Company news

Opus Genetics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Opus Genetics Announces FDA Clearance of IND Application for Gene Therapy Candidate OPGx-BEST1

August 18, 2025

Opus Genetics Announces Financial Results for Second Quarter 2025 and Provides Corporate Update

August 13, 2025

Opus Genetics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

August 5, 2025

Opus Genetics and the Global RDH12 Alliance Partner to Advance RDH12 Gene Therapy for Inherited Childhood Blindness

July 23, 2025

Opus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 3, 2025

Opus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia

June 26, 2025

Opus Genetics Awarded Non-Dilutive Funding from the RD Fund to Support Preclinical Development of OPGx-MERTK Program

June 23, 2025

Opus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast Conditions

June 2, 2025

Opus Genetics Announces Financial Results for First Quarter 2025 and Provides Corporate Update

May 15, 2025

Opus Genetics Announces Presentations on Inherited Retinal Disease Programs at Medical Conferences in May

May 12, 2025

Opus Genetics Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for OPGx-LCA5 Gene Therapy Candidate

May 6, 2025

Opus Genetics Announces Presentation of OPGX-LCA5 Gene Therapy Data at ARVO; 12 Month Phase 1/2 Results Support Potential to Restore to Meaningful Vision

May 5, 2025

Opus Genetics Announces One-Month Clinical Data from Pediatric Patient in Phase 1/2 Trial of OPGx-LCA5 Gene Therapy in Inherited Retinal Diseases

April 8, 2025

Opus Genetics Files Definitive Proxy Statement and Sends Letter to Stockholders Highlighting the Company’s Transformation and Progress

April 7, 2025

Opus Genetics to Participate in Upcoming Investor Conference in April

April 2, 2025

Opus Genetics Announces Financial Results for Full Year 2024

March 31, 2025

Opus Genetics Announces Presentation on Phentolamine Ophthalmic Solution 0.75% in Dim Light Disturbances at World Cornea Congress IX

March 21, 2025

Opus Genetics Announces Pricing of Public Offering and Concurrent Private Placement with Proceeds of Over $20 Million

March 21, 2025

Opus Genetics Announces Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting

March 5, 2025

Opus Genetics Announces FDA Fast Track and Enrollment Updates for Phentolamine Ophthalmic Solution 0.75% Programs

February 26, 2025

Opus Genetics Announces Updates on OPGx-LCA5 Clinical Program

February 18, 2025

Opus Genetics Receives FDA Agreement Under Special Protocol Assessment for Phase 3 Trial of APX3330 in Diabetic Retinopathy

December 18, 2024

Opus Genetics Announces Financial Results for Third Quarter 2024 and Provides Corporate Update

November 11, 2024

First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery

April 10, 2024

Ocuphire Provides Corporate Update: Announcing Enrollment Completion of Phase 3 Nyxol Trial, Enrollment Initiation of Nyxol Pediatric Trial, and an Investor R&D Day in January

January 4, 2022

Ocuphire’s VEGA-1 Phase 2 Trial in Presbyopia Meets Primary and Secondary Endpoints

June 29, 2021

← Newer news releases

Decks

The 5 newest of 32 decks. Every deck is listed under its year.